Blood:免疫抑制下发生的EBV相关原发性CNS淋巴瘤是一种独特的疾病

2021-03-19 MedSci原创 MedSci原创

原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见的结外非霍奇金淋巴瘤(NHL),局限于大脑、眼睛和脑脊液,不见全身性扩散的迹象。

原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见的结外非霍奇金淋巴瘤(NHL),局限于大脑、眼睛和脑脊液,不见全身性扩散的迹象。很少有PCNSL发生在免疫抑制的背景下的(如移植后淋巴细胞增生性疾病或HIV[AIDS相关PCNSL])。

发生在免疫抑制背景下的PCNSL的特征不明确,预后差,通常与EB病毒(EBV)相关。

研究人员采用靶向测序和数字多重基因表达,研究了91例具有弥漫性大B细胞淋巴瘤组织学特性的PCNSL组织的遗传图谱和肿瘤微环境(TME),并根据EBV组织和HIV状态进行分层。

检测分组示意图

47例为EBV组织阴性:45例 EBV- HIV- PCNSL和2例 EBV- HIV+ PCNSL;

44例为EBV组织阳性:23例 EBV+ HIV+ PCNSL和21例 EBV+ HIV- PCNSL。

PCNSL的突变情况统计

与既往研究一样,EBV- HIV- PCNSL经常发生MYD88、CD79B和PIM1突变,且富含激活的B细胞(ABC)起源的亚型细胞。相反,在所有EBV组织阳性病例中都没有这些突变,且ABC频率低。

HLA I/II和抗原呈递/加工基因的拷贝数变异

此外,很少观察到HLA I/II类和抗原呈递/加工基因的拷贝数缺失,提示抗原呈递功能正常。

不同状态的PCNSL的肿瘤微环境成分

研究人员进一步发现,EBV+ HIV- PCNSL具有致耐受性的TME,表现为巨噬细胞增多和免疫检查点基因表达,但与AIDS相关的PCNSL的CD4基因计数较低。

免疫抑制背景下发生的与EBV相关的PCNSL在免疫生物学上不同于EBV-HIV- PCNSL,尽管感染了免疫原性病毒,但仍具有呈递EBV抗原的能力。

原始出处:

M. K. Gandhi, et al. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood. March 18, 2021.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1236515, encodeId=442b1236515ee, content=<a href='/topic/show?id=16826468b2' target=_blank style='color:#2F92EE;'>#EB病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6468, encryptionId=16826468b2, topicName=EB病毒)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 04 08:48:17 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914271, encodeId=3bd119142e169, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed Aug 11 10:59:37 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846961, encodeId=1e81184696194, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 27 11:59:37 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950381, encodeId=6eea950381e4, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Mar 23 15:49:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480796, encodeId=87641480e96e4, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Mar 21 08:59:37 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949652, encodeId=76759496525d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Sat Mar 20 06:18:45 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949550, encodeId=14e6949550b4, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 19 18:05:11 CST 2021, time=2021-03-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1236515, encodeId=442b1236515ee, content=<a href='/topic/show?id=16826468b2' target=_blank style='color:#2F92EE;'>#EB病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6468, encryptionId=16826468b2, topicName=EB病毒)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 04 08:48:17 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914271, encodeId=3bd119142e169, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed Aug 11 10:59:37 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846961, encodeId=1e81184696194, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 27 11:59:37 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950381, encodeId=6eea950381e4, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Mar 23 15:49:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480796, encodeId=87641480e96e4, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Mar 21 08:59:37 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949652, encodeId=76759496525d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Sat Mar 20 06:18:45 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949550, encodeId=14e6949550b4, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 19 18:05:11 CST 2021, time=2021-03-19, status=1, ipAttribution=)]
    2021-08-11 lg.zhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1236515, encodeId=442b1236515ee, content=<a href='/topic/show?id=16826468b2' target=_blank style='color:#2F92EE;'>#EB病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6468, encryptionId=16826468b2, topicName=EB病毒)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 04 08:48:17 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914271, encodeId=3bd119142e169, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed Aug 11 10:59:37 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846961, encodeId=1e81184696194, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 27 11:59:37 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950381, encodeId=6eea950381e4, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Mar 23 15:49:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480796, encodeId=87641480e96e4, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Mar 21 08:59:37 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949652, encodeId=76759496525d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Sat Mar 20 06:18:45 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949550, encodeId=14e6949550b4, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 19 18:05:11 CST 2021, time=2021-03-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1236515, encodeId=442b1236515ee, content=<a href='/topic/show?id=16826468b2' target=_blank style='color:#2F92EE;'>#EB病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6468, encryptionId=16826468b2, topicName=EB病毒)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 04 08:48:17 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914271, encodeId=3bd119142e169, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed Aug 11 10:59:37 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846961, encodeId=1e81184696194, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 27 11:59:37 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950381, encodeId=6eea950381e4, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Mar 23 15:49:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480796, encodeId=87641480e96e4, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Mar 21 08:59:37 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949652, encodeId=76759496525d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Sat Mar 20 06:18:45 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949550, encodeId=14e6949550b4, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 19 18:05:11 CST 2021, time=2021-03-19, status=1, ipAttribution=)]
    2021-03-23 13d789bam70暂无昵称

    学习了,好文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1236515, encodeId=442b1236515ee, content=<a href='/topic/show?id=16826468b2' target=_blank style='color:#2F92EE;'>#EB病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6468, encryptionId=16826468b2, topicName=EB病毒)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 04 08:48:17 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914271, encodeId=3bd119142e169, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed Aug 11 10:59:37 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846961, encodeId=1e81184696194, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 27 11:59:37 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950381, encodeId=6eea950381e4, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Mar 23 15:49:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480796, encodeId=87641480e96e4, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Mar 21 08:59:37 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949652, encodeId=76759496525d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Sat Mar 20 06:18:45 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949550, encodeId=14e6949550b4, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 19 18:05:11 CST 2021, time=2021-03-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1236515, encodeId=442b1236515ee, content=<a href='/topic/show?id=16826468b2' target=_blank style='color:#2F92EE;'>#EB病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6468, encryptionId=16826468b2, topicName=EB病毒)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 04 08:48:17 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914271, encodeId=3bd119142e169, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed Aug 11 10:59:37 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846961, encodeId=1e81184696194, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 27 11:59:37 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950381, encodeId=6eea950381e4, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Mar 23 15:49:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480796, encodeId=87641480e96e4, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Mar 21 08:59:37 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949652, encodeId=76759496525d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Sat Mar 20 06:18:45 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949550, encodeId=14e6949550b4, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 19 18:05:11 CST 2021, time=2021-03-19, status=1, ipAttribution=)]
    2021-03-20 yelinghao215

    厉害

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1236515, encodeId=442b1236515ee, content=<a href='/topic/show?id=16826468b2' target=_blank style='color:#2F92EE;'>#EB病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6468, encryptionId=16826468b2, topicName=EB病毒)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Thu Aug 04 08:48:17 CST 2022, time=2022-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914271, encodeId=3bd119142e169, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Wed Aug 11 10:59:37 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846961, encodeId=1e81184696194, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sat Nov 27 11:59:37 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950381, encodeId=6eea950381e4, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=430b4201824, createdName=13d789bam70暂无昵称, createdTime=Tue Mar 23 15:49:39 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480796, encodeId=87641480e96e4, content=<a href='/topic/show?id=cce3646351' target=_blank style='color:#2F92EE;'>#EBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6463, encryptionId=cce3646351, topicName=EBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1227684795, createdName=zjshifan_98647308, createdTime=Sun Mar 21 08:59:37 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949652, encodeId=76759496525d, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e91c38967, createdName=yelinghao215, createdTime=Sat Mar 20 06:18:45 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949550, encodeId=14e6949550b4, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Mar 19 18:05:11 CST 2021, time=2021-03-19, status=1, ipAttribution=)]
    2021-03-19 jyzxjiangqin

    好文章!

    0

相关威廉亚洲官网

Gastroenterology:治疗前较虚弱的炎症性肠病患者使用免疫抑制后感染风险的明显增加

感染是免疫抑制治疗炎症性肠病(IBD)的重要不利影响因素。同时,体质虚弱与其他炎症性疾病患者的预后也有关。本项研究旨在确定IBD使用免疫抑制剂后身体虚弱与感染风险之间的关联。

Acta Neuropathologica: 多组分子图谱揭示了脑转移多种组织学共有的潜在靶向异常

脑转移(BM)是系统性恶性肿瘤的一种常见且致命的并发症,常发生在10-30%的成年癌症患者中。手术入路和药物在中枢神经系统(CNS)内渗透的固有局限性进一步使BM的治疗复杂化。

Nat Commun:黄超兰团队与高福团队等合作发现早期新冠病毒感染主要为免疫抑制并或存在“两阶段”机制

近日,北京大学医学部精准医疗多组学研究中心主任黄超兰团队,与中国科学院院士高福团队开展协同研究,发现早期的新冠感染患者存在着显着的免疫抑制。

J Immunother Cancer:营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制

该研究表明,中药复方苦参注射液通过TNFR1解除肿瘤免疫微环境中的肿瘤相关巨噬细胞(TAMs)引起的免疫抑制,从而增敏低剂量索拉菲尼的肝癌治疗效果,为肝癌的临床治疗提供了新策略。

免疫抑制剂相关儿童重度牙周炎1例

免疫抑制剂是一类可抑制机体免疫反应的药物,其在临床上主要用于防止器官移植后的排异反应及自身免疫性疾病的治疗。免疫抑制剂除了会出现骨髓抑制、肝功受损等全身副作用,还会导致口腔局部的病变

BMJ:奠基性试验!调节性T细胞移植有望克服器官移植的免疫抑制等问题

长期免疫抑制是目前实体器官移植的护理标准。尽管患者和同种异体移植的生存期已有进展,但在过去的二十年中长期效果并未改善。慢性排斥反应和慢性免疫抑制的长期并发症。